A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors
This study is testing a new medication called sacituzumab tirumotecan to see if it works better than standard chemotherapy for people with a specific type of advanced lung cancer. It is meant for patients whose cancer has continued to grow even after taking targeted treatments called EGFR inhibitors.
This trial is for adults with advanced non-small cell lung cancer who have a specific genetic change (EGFR mutation). You may be eligible if your previous cancer treatments have stopped working and your overall health is stable.
Participants will be randomly assigned to receive either the new study drug or a combination of two standard chemotherapy medicines. Throughout the study, you will be closely monitored by a medical team and receive supportive medications to help keep you comfortable and manage any side effects.
This study is currently active but not recruiting new participants. Research locations include Oakland, Roseville, and San Francisco, California.
- 1The study compares a new targeted drug to standard platinum-based chemotherapy.
- 2It is specifically designed for patients who have already tried EGFR inhibitor treatments.
- 3The primary goal is to see which treatment helps patients live longer.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.